At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
argatrobandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multi-centre, Clinical Study to Collect Information on the Clinical Use of Argatroban in Patients With Heparin Induced Thrombocytopenia (HIT) Type II Who Require Parenteral Antithrombotic Therapy
In Brief
A Phase 2 clinical trial evaluating argatroban for Heparin-induced Thrombocytopenia Type II. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to collect data on the clinical management of Argatroban in patients with suspected or confirmed heparin-induced thrombocytopenia Type II, with or without ongoing thrombosis who require parenteral antithrombotic therapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeparin-induced Thrombocytopenia Type II
CountriesFrance
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2009
Enrollment StartApr 2009
Primary CompletionFeb 2011
TodayJul 2026
First PostedMar 13, 2009
Enrollment StartApr 1, 2009
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.3 years ago
Interventions
argatrobandrug